Defendant Name: Cumberland Pharmaceuticals Inc.

Defendant Type: Public Company
SIC Code: 2834
CUSIP: 23077010

Initial Case Details

Legal Case Name In the Matter of Cumberland Pharmaceuticals Inc.
First Document Date 27-Sep-2023
Initial Filing Format Administrative Action
File Number 3-21738
Allegation Type Other

Violations Alleged

Exchange Act
• Sec 13(a)
• Rule 13a-1

Related Violations Alleged

Cumberland Pharmaceuticals Inc. is alleged to have caused an unidentified individual or entity's violation of Section 16(a) Exchange Act; Rule 16a-3 Exchange Act.

Resolutions

First Resolution Date 27-Sep-2023
Headline Total Penalty and Disgorgement $200,000

Related Documents:

34-98553 27-Sep-2023 Administrative Proceeding
Order Instituting Cease-and-Desist Proceedings Pursuant to Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing a Cease-and-Desist Order
On September 27, 2923, the SEC instituted settled cease-and-desist proceedings against Cumberland Pharmaceuticals Inc., stating: "These proceedings arise out of violations of the issuer reporting requirements and beneficial ownership reporting requirements of the federal securities laws."
2023-201_3-21738 27-Sep-2023 Press Release--Administrative Proceeding
SEC Charges Corporate Insiders for Failing to Timely Report Transactions and Holdings; Several issuers charged as well in connection with their insiders' reporting failures
On September 27, 2021, the SEC "announced charges against six officers, directors, and major shareholders of public companies for failing to timely report information about their holdings and transactions in company stock. Five publicly-traded companies were also charged for contributing to the filing failures by insiders or failing to report their insiders' filing delinquencies."